Poorly Differentiated Thyroid Cancer: Experience Of 9 Cases In The Nuclear Medicine Department Of CHU Hassan II Of Fez

Background: Poorly Differentiated Thyroid Carcinoma (PDTC) is a rare and aggressive form of thyroid cancer, representing 1% to 3% of all thyroid malignancies. This study evaluates the clinical, biological, and therapeutic characteristics of 9 patients treated at the Nuclear Medicine Department of CHU Hassan II in Fez. The aim is to analyze the efficacy of high-dose radioiodine therapy and alternative treatments in patients who exhibit iodine-131 refractoriness. Materials and Methods: In this retrospective study, 9 patients diagnosed with PDTC and treated with highdose radioiodine therapy were analyzed. Clinical parameters such as age, sex, metastasis at diagnosis, iodine refractoriness, and therapeutic response were evaluated. Patients refractory to radioiodine therapy were treated with sorafenib. Survival rates and follow-up outcomes were assessed over 24 months. Results: The median age was 58 years, with a female predominance (67%). Initial metastases were present in 5 patients (55%). Three patients (33%) were refractory to iodine-131 and received sorafenib. The overall survival rate at 24 months was 89%. Despite aggressive therapies, radioiodine-refractory patients demonstrated poorer prognoses. Conclusion: Poorly Differentiated Thyroid Carcinoma remains a challenging malignancy due to its aggressiveness and frequent iodine-131 refractoriness. High-dose radioiodine therapy is effective in selected patients, but targeted therapies such as sorafenib are crucial for refractory cases to improve outcomes.